Takeda Pharmaceutical redeems $300 million of 2.45% senior notes due 2022

By Rebecca Melvin

New York, Feb. 26 – Takeda Pharmaceutical Co., Ltd. redeemed at its option $300 million of its $500 million outstanding principal amount of 2.45% notes due 2022, according to a company notice.

After completion of the partial redemption on Thursday, $200 million of the notes that were originally issued in July 2017 will remain outstanding.

The pharmaceutical company is based in Osaka, Japan.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.